Neovacs S.A. (ALNEV.PA)

EUR 1.11

(-11.15%)

Long Term Debt Summary of Neovacs S.A.

  • Neovacs S.A.'s latest annual long term debt in 2023 was 650 Thousand EUR , down -45.83% from previous year.
  • Neovacs S.A.'s latest quarterly long term debt in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • Neovacs S.A. reported annual long term debt of 1.2 Million EUR in 2022, up 4131.31% from previous year.
  • Neovacs S.A. reported annual long term debt of 28.36 Thousand EUR in 2021, down -63.81% from previous year.
  • Neovacs S.A. reported quarterly long term debt of 650 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.
  • Neovacs S.A. reported quarterly long term debt of 650 Thousand EUR for 2023 FY, down -45.83% from previous quarter.

Annual Long Term Debt Chart of Neovacs S.A. (2023 - 2009)

Historical Annual Long Term Debt of Neovacs S.A. (2023 - 2009)

Year Long Term Debt Long Term Debt Growth
2023 650 Thousand EUR -45.83%
2022 1.2 Million EUR 4131.31%
2021 28.36 Thousand EUR -63.81%
2020 78.36 Thousand EUR 32.81%
2019 59 Thousand EUR -3.34%
2018 61.03 Thousand EUR -91.8%
2017 743.97 Thousand EUR -7.53%
2016 804.58 Thousand EUR 8.97%
2015 738.34 Thousand EUR -42.7%
2014 1.28 Million EUR -65.98%
2013 3.78 Million EUR 12.12%
2012 3.37 Million EUR 290.18%
2011 865.73 Thousand EUR 20.57%
2010 718.06 Thousand EUR -81.86%
2009 3.95 Million EUR 0.0%

Peer Long Term Debt Comparison of Neovacs S.A.

Name Long Term Debt Long Term Debt Difference
ABIONYX Pharma SA 1.1 Million EUR 40.963%
ABIVAX Société Anonyme 44.69 Million EUR 98.546%
Adocia SA 4.54 Million EUR 85.683%
Aelis Farma SA 2.04 Million EUR 68.262%
Biophytis S.A. 3.11 Million EUR 79.106%
Advicenne S.A. 15.89 Million EUR 95.911%
genOway Société anonyme 5.51 Million EUR 88.223%
IntegraGen SA 642.28 Thousand EUR -1.202%
Medesis Pharma S.A. 1.2 Million EUR 45.833%
NFL Biosciences SA 39.2 Thousand EUR -1558.036%
Plant Advanced Technologies SA 4.35 Million EUR 85.08%
Quantum Genomics Société Anonyme 1.96 Million EUR 66.842%
Sensorion SA 1.24 Million EUR 47.619%
Theranexus Société Anonyme 2.46 Million EUR 73.585%
TME Pharma N.V. - EUR -Infinity%
Valbiotis SA 3.89 Million EUR 83.325%
TheraVet SA 1 Million EUR 35.039%
Valerio Therapeutics Société anonyme 6.9 Million EUR 90.588%
argenx SE 15.35 Million EUR 95.767%
BioSenic S.A. 15.57 Million EUR 95.826%
Celyad Oncology SA 902 Thousand EUR 27.938%
DBV Technologies S.A. 4.52 Million USD 85.639%
Galapagos NV 4.94 Million EUR 86.853%
Genfit S.A. 62.25 Million EUR 98.956%
GeNeuro SA 6.49 Million EUR 89.988%
Hyloris Pharmaceuticals SA 344 Thousand EUR -88.953%
Innate Pharma S.A. 30.6 Million EUR 97.876%
Inventiva S.A. 25.61 Million EUR 97.463%
MaaT Pharma SA 5.42 Million EUR 88.018%
MedinCell S.A. 52.8 Million EUR 98.769%
Nanobiotix S.A. 41.66 Million EUR 98.44%
Onward Medical N.V. 16.3 Million EUR 96.014%
Oryzon Genomics S.A. 3.45 Million EUR 81.163%
OSE Immunotherapeutics SA 35.5 Million EUR 98.169%
Oxurion NV 117 Thousand EUR -455.556%
Pharming Group N.V. 123.65 Million EUR 99.474%
Poxel S.A. 40.14 Million EUR 98.381%
GenSight Biologics S.A. 1.04 Million EUR 37.977%
Transgene SA 17 Thousand EUR -3723.529%
Financière de Tubize SA - EUR -Infinity%
UCB SA 2.87 Billion EUR 99.977%
Valneva SE 132.76 Million EUR 99.51%
Vivoryon Therapeutics N.V. - EUR -Infinity%